Fixed-dose combination: DPP-4 inhibitor plus biguanide
Updated · Methodology
Second line
Type 2 diabetes in adults with above target on metformin monotherapy. Per / 2024 and redGDPS 2024, second-line when ASCVD, HF, and CKD are absent. Dose: 50/850, 50/1000 mg twice daily with meals (Janumet) or 100/1000 mg once daily (Janumet XR). HbA1c at 3 months. With ASCVD, HFrEF, or CKD, GLP-1 RA or SGLT2 inhibitor takes priority.
Sources
ICD-10: E11 · ICD-11: 5A11
Sitagliptin inhibits DPP-4 and prolongs endogenous GLP-1 and GIP action – glucose-dependent insulin secretion rises and glucagon falls. Metformin lowers hepatic gluconeogenesis and improves insulin sensitivity. TECOS (NEJM 2015) confirmed sitagliptin's cardiovascular safety: neutral MACE effect.
Metformin is permitted in pregnancy for type 2 diabetes or gestational diabetes. Sitagliptin is not studied – switch to insulin.
Metformin is compatible with breastfeeding (RID 0.28–0.65%, Hale L1). No milk data for sitagliptin – prefer metformin monotherapy or insulin in nursing women.
Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.
Opens the checker prefilled with this drug. Pick the second one from your regimen.
Summary of a multi-drug list →
Medicine list: everything you take in one place →
Sitagliptin + Metformin is evaluated for the following indications with varying evidence strength: Type 2 diabetes mellitus (evidence tier A). See the full indication matrix with dosing and citations above on this page.
Common side effects of Sitagliptin + Metformin (≥ 1 in 100): Nausea, diarrhea, metallic taste (metformin), Headache, Nasopharyngitis, Hypoglycemia when combined with sulfonylurea or insulin. See the Safety section for uncommon and serious reactions.
Metformin is permitted in pregnancy for type 2 diabetes or gestational diabetes. Sitagliptin is not studied – switch to insulin.
Metformin is compatible with breastfeeding (RID 0.28–0.65%, Hale L1). No milk data for sitagliptin – prefer metformin monotherapy or insulin in nursing women.
Sitagliptin + Metformin is contraindicated in: Hypersensitivity; Type 1 diabetes; Diabetic ketoacidosis; Severe renal impairment (CrCl <30); Acute conditions with renal risk (dehydration, shock, sepsis). Full list in the Safety section.
Tirzepatide, Vildagliptin, Vildagliptin + Metformin, Dapagliflozin, Insulin, Insulin glulisine, Metformin, Empagliflozin